Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions

Heterobifunctional degraders, known as proteolysis targeting chimeras (PROTACs), theoretically possess a catalytic mode-of-action, yet few studies have either confirmed or exploited this potential advantage of event-driven pharmacology. Degraders of oncogenic EML4-ALK fusions were developed by conju...

Celý popis

Podrobná bibliografia

Vydané v:	Journal of medicinal chemistry Ročník 66; číslo 8; s. 5524
Hlavní autori:	Gao, Yang, Jiang, Baishan, Kim, Hellen, Berberich, Matthew J, Che, Jianwei, Donovan, Katherine A, Hatcher, John M, Huerta, Fidel, Kwiatkowski, Nicholas P, Liu, Yingpeng, Liuni, Peter P, Metivier, Rebecca J, Murali, Vineeth K, Nowak, Radosław P, Zhang, Tinghu, Fischer, Eric S, Gray, Nathanael S, Jones, Lyn H
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 27.04.2023
Predmet:	Anaplastic Lymphoma Kinase Antineoplastic Agents - pharmacology Drug Resistance, Neoplasm Humans Lung Neoplasms - drug therapy Mutation Oncogene Proteins, Fusion - genetics Protein Kinase Inhibitors - pharmacology Receptor Protein-Tyrosine Kinases
ISSN:	1520-4804, 1520-4804
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!